Unapproved research chemicalHuman evidence

DSIP

Also referred to as Delta sleep-inducing peptide

The name is considerably stronger than the evidence. The published sleep findings are old, small, and inconsistent.

Molecule class: Nonapeptide
Category: Sleep
Last evidence review: 2026-08-24

Compare this compound Check interactions Solution calculator

Human studies

Animal / in vitro

Graded claims

—

Participants

Mechanism

What is being studied

Originally isolated from rabbit cerebral venous blood during induced sleep. A specific receptor and a coherent mechanism have not been established.

Evidence

Claims, graded individually

Each statement below carries its own evidence level, its own confidence rating, and its own account of what remains unestablished. A compound does not have a single grade.

Sleep & Circadian Research

XInsufficient / conflictingVery low confidenceHuman evidence

Historical human studies of DSIP and sleep architecture produced inconsistent findings.

What is not established

Small, dated, inconsistent studies. The compound's name is not an evidence claim.

Supporting sources (1)

Case seriesHumanNo verified identifier on file

Delta sleep-inducing peptide in sleep research

Multiple · Sleep and neuroscience literature · 1990

Population: Small human cohorts, chiefly from the 1970s–1990s
Endpoint: Sleep architecture, latency, and subjective sleep quality
Route: Intravenous in most of the reported work
Quantity as reported: Reported in the historical literature
Frequency: Varies

Result. Findings across the small historical studies are inconsistent.

Adverse events. Not systematically characterised.

Limitations. Old, small, methodologically dated studies with inconsistent results. The name overstates the strength of the sleep evidence.

Search PubMed for this literature →

Last evidence review: 2026-08-23

Human evidence

1 human study catalogued

Human and non-human evidence are kept strictly separate. They are never pooled, averaged, or presented as a single body of support.

Case seriesHumanNo verified identifier on file

Delta sleep-inducing peptide in sleep research

Multiple · Sleep and neuroscience literature · 1990

Population: Small human cohorts, chiefly from the 1970s–1990s
Endpoint: Sleep architecture, latency, and subjective sleep quality
Route: Intravenous in most of the reported work
Quantity as reported: Reported in the historical literature
Frequency: Varies

Result. Findings across the small historical studies are inconsistent.

Adverse events. Not systematically characterised.

Limitations. Old, small, methodologically dated studies with inconsistent results. The name overstates the strength of the sleep evidence.

Search PubMed for this literature →

Pharmacology

Reported parameters

Half-life

Not characterised

Reported as very short in the historical literature.

Routes studied

Intravenous
Subcutaneous

Evidence from one route does not transfer to another. Topical, oral, and injected administration can produce entirely different exposure from the same quantity.

Regulatory status

Not approved for human use. FDA removed emideltide (DSIP) from the Category 2 list effective 22 April 2026. The Pharmacy Compounding Advisory Committee then voted AGAINST including it on the 503A bulks list on 23-24 July 2026 — the only one of the seven peptides considered at that meeting to be voted down.

Storage as documented

No approved labelling exists.

Safety

Signals reported in the literature

This lists what has been reported. It is not a complete safety profile, and for several compounds in this catalogue no systematic safety surveillance exists at all.

Human safety is not systematically characterised

Limitations

What the evidence cannot tell you

Given as much prominence as the findings, because for most compounds in this category it is the more important half.

Historical studies are small and methodologically dated
Results are inconsistent across the available reports
The compound's name should not be read as an evidence claim

Reference

Evidence grading key

AStrong

Multiple high-quality human trials, or strong systematic-review or meta-analytic evidence.

BModerate

Human controlled evidence exists, but replication or sample size is limited.

CPreliminary

Small human studies, observational evidence, or early-phase clinical work.

DPreclinical

Predominantly animal or in-vitro evidence. No adequate human outcome data.

EMechanistic

Biological plausibility or mechanistic reasoning without adequate outcome evidence.

XInsufficient / conflicting

Evidence is absent, irreconcilable, or too weak to support any directional statement.